SCHEMBL31408351

SCHEMBL31408351

CC(=O)NCc1cc2cc(Cl)c(-c3cnc(C)nc3)cc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MAPT P10636 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MTNR1A P48039 5/20 0.37
▸ MTNR1B P49286 4/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ RAB9A P51151 2/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ PRKAB2 O43741 2/20 0.33
▸ PRKAG1 P54619 2/20 0.33
▸ PRKAA2 P54646 2/20 0.33
▸ PRKAA1 Q13131 2/20 0.33
▸ PRKAG3 Q9UGI9 2/20 0.33
▸ PRKAG2 Q9UGJ0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31408461 0.88 SMN1; SMN2 (0.43) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408473 0.86 SMN1; SMN2 (0.37) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408629 0.86 PTGES (0.42) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408448 0.86 RAB9A (0.38) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408611 0.86 SMN1; SMN2 (0.41) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408594 0.85 SMN1; SMN2 (0.38) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408586 0.85 SMN1; SMN2 (0.40) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408238 0.85 SMN1; SMN2 (0.40) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408250 0.84 PRKAG1 (0.48) SMN1; SMN2MAPTKDM4EALDH1A1MTNR1A
SCHEMBL31408354 0.84 PRKAG1 (0.48) SMN1; SMN2MTNR1AMTNR1BPRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049604-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
Send feedback